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 Implication for health policy/practice/research/medical education:
Corticosteroid treatment may be eﬀective for itraconazole-induced hepatitis for those who do not response to conservative treat-
ment.  
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Background: Itraconazole is believed to carry a low risk of hepatic toxicity 
owing to its low aﬃnity for the human P-450 enzyme. Therefore, hepatic fail-
ure caused by itraconazole is exceedingly rare.
Objectives: We report the case of a 46-year-old woman who developed hepatic 
failure related to itraconazole that was administered for the treatment of 
onychomycosis. Her condition deteriorated after withdrawal of the drug, fol-
lowed solely by supportive care initially.
Case Report: Treatment with corticosteroids was started 10 days after her ad-
mission, and her condition gradually improved. Unfortunately, her condition 
worsened when the dosage of corticosteroids was abruptly decreased. Ultim-
ately, her condition improved with appropriate adjustments of corticosteroid 
dosage.
Discussion: We conclude that corticosteroid therapy may be eﬀective for 
itraconazole-induced hepatitis, especially in those patients who do not re-
spond to conservative treatment. Notably, any decrease in the dosage should 
be performed with caution. We also recommend that close monitoring of liver 
function is mandatory during the use of itraconazole.
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1. Background
Itraconazole has been subjected to thorough clinical 
evaluation since 1983. It has been extensively used in the 
treatment of superﬁcial mycoses including vaginal and 
oral candidiasis, dermatophytosis, and systemic mycoses 
(1). The most frequently reported adverse events are gas-
trointestinal disturbance and skin reactions. The rate of 
abnormal results of liver function tests and severe hepa-
titis among itraconazole users has been estimated to be 
3% and less than 2%, respectively. In most cases, patients 
recover spontaneously after discontinuation of itracon-
azole treatment and administration of supportive treat-
ment. However, the liver function of patients receive 
long-term therapy should be closely monitored, because 
liver dysfunction in these patients has been reported to 
be fatal. Liver transplantation in such cases is reserved 
for those patients who show severe liver damage.844
Hepat Mon. 2011;11(10):843-846
Lou  HY  et  al                                   Itraconazole; Corticosteroid
2. Objectives
Corticosteroids are widely used in the treatment of a 
variety of autoimmune diseases. Only a few case reports 
on the usage of corticosteroids for the treatment of drug-
induced hepatitis are available. In this study, we report 
the successful use of corticosteroids in the treatment of 
hepatic failure caused by itraconazole. 
3. Case Report
A 46-year-old woman with anorexia and jaundice was 
admitted to the Taipei Medical University Hospital. Her 
medical history was unremarkable, except for onycho-
mycosis of both toes, which had been treated with itra-
conazole (200 mg daily) for 5 weeks. She gradually de-
veloped symptoms of weakness and nausea. Generalized 
pruritus developed 1 week before admission. On exami-
nation, she was found to have jaundice without abdomi-
nal tenderness or hepatosplenomegaly. The initial labo-
ratory data were as follows: alanine transaminase (AST), 
2571 IU/L; aspartate transaminase (ALT), 3789 IU/L; total 
bilirubin, 4.4 mg/dL; albumin, 3.1 g/dL; prothrombin 
time, 13.57 s; and international normalized ratio (INR), 
1.43. The test results for serum antinuclear antibody and 
anti-smooth muscle antibody were negative; moreover, 
a viral hepatitis survey that included tests for hepatitis 
A, B, C, and E yielded negative results. Five days after her 
admission, multiple erythematous papules appeared on 
her lower extremities. A skin biopsy showed prominent 
perivascular lymphocytes and occasionally eosinophil 
inﬁltrations. The epidermis showed focal spongiosis, 
basal layer vacuolization, leukocyte exocytosis, and ke-
ratinocyte necrosis (Figure 1). The pathological ﬁndings 
were compatible with a clinical diagnosis of erythema 
multiforme. Her condition deteriorated despite support-
ive treatment. She developed ascites 10 days after admis-
sion. The results of her liver chemistry tests were as fol-
lows: AST, 532 IU/L; ALT, 1298 IU/L; total bilirubin, 12.8 mg/
dL; albumin, 2.3 g/dL; prothrombin time, 18.35 s; and INR, 
2.77. Intravenous methylprednisolone was initially ad-
ministered at 40 mg every 8 hours, and the dose was grad-
ually decreased to 20 mg every 12 hours over the course 
of 1 week. Her condition dramatically improved, and the 
ascites disappeared completely. The laboratory data were 
as follows: total bilirubin, 8.8 mg/dL; prothrombin time, 
12.75 s; and INR, 1.24. Thereafter, 10 mg of oral predniso-
lone was administered every 12 hours to replace the 20 
mg intravenous methylprednisolone. However, her con-
dition deteriorated to some extent after this change, and 
her total bilirubin level reached 12.7 mg/dL. A liver biopsy 
detected cholestatic hepatitis with marked bile plugs 
that were accumulated in the canaliculi and surrounded 
by hepatocytes in a rossetting pattern. Degeneration of 
hepatocytes indicated by a prominent, pericentral zonal 
ballooning was observed (Figure 2). Patchy necrosis of 
the hepatocytes was also noted. In the portal and peri-
portal areas, lymphocyte and neutrophil inﬁltration was 
observed. The patient’s condition was consistent with 
acute cytotoxic and cholestatic injuries caused by drug-
induced hepatotoxicity. Intravenous injection of 20 mg 
methylprednisolone was restarted and administered 
every 8 hours. This dosage was gradually decreased over 
the following 2 weeks. The patient’s condition stabilized 
after this adjustment. She was discharged 36 days after 
her admission. The laboratory data at the time of dis-
charge were as follows: total bilirubin, 3.3 mg/dL; AST, 116 
IU/L; and ALT, 186 IU/L. The levels of the parameters mea-
sured during the course of the disease are shown in Table. 
Oral prednisolone at 5 mg daily was continued for 1 week 
after her discharge from the hospital. After 2 weeks, her 
liver chemistry test results returned to normal.
4. Discussion
Itraconazole is an antifungal agent used in the treat-
ment of deep and superﬁcial fungal infections. It impairs 
the conversion of lanosterol to ergosterol by inhibiting 
the fungal cytochrome P450-dependent enzyme. The ef-
fect of itraconazole on the mammalian cytochrome 
P450 is lesser than that of other azoles, thereby suggest-
ing a lesser eﬀect on human steroidogenesis (2). There-
Figure 1. Epidermal Changes in Erythema Multiforme with Vacuolated 
Degeneration of Basal Cells ( ) and Scattered Individual Keratinocyte 
Necrosis ( ). Hematoxylin and Eosin, 200×
Figure 2. Degeneration of Hepatocytes Indicated by a Prominent, Cen-
trilobular Zonal Ballooning ( ) with Cholestasis in the Bile Canaliculi ( ). 
Hematoxylin and Eosin, 200×845
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fore, hepatotoxic reactions caused by itraconazole have 
only rarely been reported. Adverse reactions to itracon-
azole include skin eruptions, gastrointestinal upset, 
thrombocytopenia, headache, dizziness, reversible ede-
ma of the extremities, gynecomastia, hypokalemia, and 
hypertriglyceridemia (3). The level of serum transami-
nases increases in 1%–5% of patients who receive continu-
ous therapy (4, 5). Symptomatic hepatitis rarely occurs 
and, when it does, recovery generally ensues with the ces-
sation of medication (6). The recovery period varies, as 
reported in the literature. Talwalkar et al. reported a case 
of severe cholestasis related to itraconazole usage. The 
period of recovery from symptomatic hepatitis in the pa-
tient in that case was 5 months without any speciﬁc treat-
ment (7). In our study, we encountered a patient with se-
vere hepatitis who developed hypoalbuminemia, ascites, 
jaundice, and coagulopathy. The case of this patient was 
diﬀerent from most cases that have been reported by 
others, because her condition was protracted even after 
discontinuation of itraconazole therapy. Corticosteroids 
have well established eﬃcacy in the treatment of auto-
immune hepatitis. However, only a few reports on the 
successful treatment of drug-induced hepatitis by cor-
ticosteroids are available. These include reports on the 
treatment of drug-induced hepatitis by troglitazone (8) 
and ticlopidine (9). Prednisolone had been used in the 
treatment of itraconazole-related hepatitis in 2 patients 
(10, 11), but the liver damage in both the patients was not 
as severe as that in our patient. Our patient’s condition 
dramatically improved after corticosteroid treatment; 
however, she experienced a relapse when the dosage was 
abruptly reduced. Subsequently, she recovered after ad-
ministration of adequate doses of corticosteroids. This 
observation implies that the response is highly corti-
costeroid dependent, a correlation that has never been 
reported in the literature. However, the mechanism un-
derlying the treatment of itraconazole-related hepatitis 
by corticosteroids remains obscure and requires further 
investigation. Reports on the pathological features of 
itraconazole-induced hepatitis are still limited. Both cy-
tolytic and cholestatic hepatitis have been reported to 
be caused by itraconazole administered at certain doses 
(12). According to Adriaenssen’s (13) report of itracon-
azole-induced hepatitis in 3 patients, all the patients de-
veloped cholestatic liver injury with damage to the inter-
lobular bile ducts. In addition, 2 of these patients showed 
ducopenia. None of them showed clinical hallmarks of 
an immunologic idiosyncrasy such as fever, rashes, or 
eosinophilia. The author concluded that itraconazole-
induced hepatitis is a metabolic rather than an immu-
noallergic idiosyncrasy. In contrast, histological evalu-
ations by Tuccori (14) and Srebrnik (15) showed massive 
panlobular necrosis. Both of their patients showed a pat-
tern of cytolytic liver injury without a skin reaction, and 
both required liver transplantation. In our patient, the 
predominant manifestation was a hepatocellular type 
of injury. She also developed fever and erythema mul-
tiforme. A similar case has not been reported in the lit-
erature. Whether pathological presentation is correlated 
with clinical management deserves further study.
The incidence of cutaneous reactions induced by itra-
conazole is 4%–8.6%, according to various studies (3). A 
population-based survey from Spain enrolled 61858 pa-
tients to explore the risk of serious skin disorders among 
users of oral antifungal products (16). Only 2 of 15329 itra-
conazole users developed serious, adverse skin reactions; 
1 user developed angioedema, and the other, erythema 
multiforme. Other sporadic cases of cutaneous events 
associated with itraconazole include acute generalized 
exanthematic pustulosis, purpuric eruption, and inﬁl-
trative erythematous papules and macules (17).
According to an investigation by Tuccori (14), fatal hepa-
titis can develop after itraconazole treatment. At present, 
liver transplantation is used to treat patients with drug-
induced hepatic failure. Our review of the literature 
showed 3 deaths caused by itraconazole-associated hepa-
totoxicity (14). Srebrnik reported the case of a patient 
with itraconazole-induced hepatic failure who survived 
after a successful liver transplantation (15). Our results 
show the beneﬁts of corticosteroids in the management 
of itraconazole-induced hepatic failure. In summary, 
monitoring of liver function during itraconazole use is 
important. Most of the hepatic injuries induced by itra-
conazole are self-limited, and patients generally recover 
after withdrawal of the oﬀending drug. However, cortico-
steroid treatment should be used if the patient does not 
improve after a conservative treatment.
AST a, 
(0-40 IU/L)
ALT a, 
(0-40 IU/L)
Total Bilirubin, 
(0-1.4 mg/dL)
Albumin, 
(3.5-5.2 g/dL)
Prothrombin Time, 
(8.0-12.0 sec)
INR a, 
(0.85-1.15)
Initial 2571 3789 4.4 3.1 13.57 1.43
10 days after admission 532 1298 12.8 2.3 18.35 2.77
After methylprednisolone
injection
188 641 8.8 2.9 12.75 1.24
Rapid switch to oral 
prednisolone
168 398 12.7 2.7 12.17 1.17
Before discharge 116 186 3.3 3.1 11.22 0.94
Table. The Level of Various Laboratory Parameters at Diﬀerent Time Point of the Disease Course
a Abbreviations: ALT, alanine aminotransferase; AST, aspartate amoniteransferase; INR; international normalized ratio846
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